Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06836856
Recruiting Phase 1/2

Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

NCT06836856 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University
Phase
Phase 1/2
Started
2025-01-20
Last updated
2025-04-02

Condition(s) studied

TBI Traumatic Brain Injury

Investigational drug(s) / intervention(s)

controlpropranolol →Carvedilol →

control: Patients will receive standard care with no interventions until end of treatment.

propranolol: starting at 20mg propranolol three times daily by mouth or per feeding tube. The dose was increased daily in 20mg three times daily increments (60mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 640mg/day in addition to standard care until end of treatment.

Carvedilol: starting at 6.25mg carvedilol three times daily by mouth or per feeding tube. The dose was increased daily in 6.25 mg three times daily increments (18.75 mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 100 mg/day in addition to standard care until end of treatment.

Study summary

Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1\. Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries. Minor injuries are defined as presence of any of the following: 1. Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound. 2. mild lung contusion detected in the chest CT scan. 3. hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress. 4. simple limb fractures. Exclusion Criteria: 1. Patients on pre-injury beta-blocker therapy. 2. Patients with any bronchospastic conditions. 3. Patients with active acute coronary syndrome. 4. TBI with GCS ≤ 13 with associated major injuries defined as the presence of any of the following: 1. Moderate \& marked IPFF requiring surgical intervention ( laparotomy ). 2. moderate \& marked lung contusion, pneumothorax \& hemothorax with accompanying symptoms of hypoxia, tachypnea, lower limbs, or limb amputation. 3. Compound fracture in the upper or lower limb. 4. Open Faciomaxillary trauma. 5. Patients with persistent shock (systemic blood pressure \<100 mmHg, base deficit \> 4, or oliguria , HR \< 60 b/min ) after \> one week of admission.

Primary outcome measure(s)

  • Incidence of In-hospital mortality — 14 days
    Difference between the study grous in terms of the percentage of all-cause mortality at the end of treatment

Trial sites (2)

FacilityCityRegionStatus
Zagazig University Hospitals, Zagazig, Zagazig Egypt Recruiting
Zagazig University Hospitals Zagazig Egypt Not Yet Recruiting

On this site

📄 Coreg (carvedilol) drug profile →

More Mansoura University trials in Egypt

PCNL Versus RIRS for Management of Stones in Solitary Kidney Active, not recruiting
Role of HFNC During FOB in Patients With Respiratory Failure Recruiting
FANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial Starting soon
Fully Versus Partially Guided Implants Placement: Measurement of Accuracy of Implant Position and Passivity of Superstructures. Active, not recruiting
Maxillary and Mandibular Nerve Block Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06836856 on ClinicalTrials.gov ↗ ← All trials in Egypt